Cannabinoid · Pharmaceutical
Dexanabinol (HU-211) is a pharmaceutical cannabinoid, in the Synthetic (NMDA antagonist) group. A non-psychotropic synthetic that acts as an NMDA antagonist rather than a CB agonist.
Where it fits
Dexanabinol (HU-211) derives from Synthetic. See the Synthetic & altered cannabinoids index for how it relates to the rest of the family.
What the research shows
Dexanabinol (HU-211) has trials (investigational)-level evidence; see the class index and related compounds for cited studies.
FAQ
Is HU-211 intoxicating? No. Dexanabinol (HU-211) is non-intoxicating.
Where does HU-211 come from? Dexanabinol (HU-211) is a wholly synthetic (3S,4S) cannabinoid enantiomer first synthesized at the Hebrew University of Jerusalem.
Why is HU-211 non-intoxicating while HU-210 is extremely potent? HU-211 is the mirror-image (3S,4S) stereoisomer of (-)-HU-210; because human CB1 receptors bind only the (3R,4R) configuration, HU-211 does not activate CB1 and instead blocks NMDA glutamate channels.
Enantiomeric Pharmacology and Traumatic Brain Injury Trials
Dexanabinol (HU-211) is the synthetic (+)-(3S,4S) enantiomer of the potent classical cannabinoid agonist HU-210, which itself is a 1,1-dimethylheptyl analogue of delta-8-THC. Because CB1 and CB2 cannabinoid receptors are strictly stereoselective for the (-)-(3R,4R) configuration, (+)-HU-211 exhibits negligible affinity for cannabinoid receptors and produces no cannabimimetic intoxication; instead, Feigenbaum et al. (1989) demonstrated that it acts as a stereospecific non-competitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor ion channel (PubMed PMID 2549466). In clinical development for severe traumatic brain injury (TBI), a randomized phase II study by Knoller et al. (2002) reported improved intracranial pressure control inside neurosurgical intensive care units (PubMed PMID 11912529), whereas the definitive multi-center phase III randomized controlled trial across 861 patients published by Maas et al. (2006) in The Lancet Neurology confirmed biological safety but found no statistically significant improvement in 6-month Glasgow Outcome Scale scores over placebo (PubMed PMID 16361021).
Part of the NOIDS cannabinoids index. Educational reference, not medical advice.